Cita APA

de Boer, N. L., van Kooten, J. P., Burger, J. W. A., Verhoef, C., Aerts, J. G. J. V., & Madsen, E. V. E. (2019). Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: Rationale and design of the MESOPEC trial. BMJ Open.

Chicago Style Citation

de Boer, Nadine L., Job P. van Kooten, Jacobus W A. Burger, Cornelis Verhoef, Joachim G J V. Aerts, i Eva V E. Madsen. "Adjuvant Dendritic Cell Based Immunotherapy (DCBI) After Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Mesothelioma, a Phase II Single Centre Open-label Clinical Trial: Rationale and Design of the MESOPEC Trial." BMJ Open 2019.

Cita MLA

de Boer, Nadine L., et al. "Adjuvant Dendritic Cell Based Immunotherapy (DCBI) After Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Peritoneal Mesothelioma, a Phase II Single Centre Open-label Clinical Trial: Rationale and Design of the MESOPEC Trial." BMJ Open 2019.